Shujun Pei1, Feng Zhao2, Junle Liu2, Qiang Fu2, Peizhong Shang3. 1. Department of Anesthesiology, Chinese PLA 251 Hospital Zhangjiakou, China ; Department of Anesthesiology, Chinese PLA General Hospital Beijing, China. 2. Department of Anesthesiology, Chinese PLA General Hospital Beijing, China. 3. Department of General Surgery, Chinese PLA 251 Hospital Zhangjiakou, China.
Abstract
BACKGROUND: Glioma is the most devastating type of malignant brain tumors in adults. Genetic factors play important roles in the pathogenesis of glioma. In recent years, some studies found that there were significant association between regulator of telomere elongation helicase 1 rs6010620 polymorphism and glioma susceptibility, however, the results were controversial. The aim of this study was to obtain a more exact estimation of the association between regulator of telomere elongation helicase 1 rs6010620 polymorphism and glioma through a meta-analysis. METHODS: The meta-analysis included 19 published case-control studies involving 8541 cases and 14226 controls. The included papers were searched from PubMed and Embase database. Odds ratio (OR) with 95% confidence interval (95% CI) were used to evaluate the association of regulator of telomere elongation helicase 1 rs6010620 polymorphism with glioma. RESULTS: A significant association between regulator of telomere elongation helicase 1 rs6010620 polymorphism and glioma susceptibility was observed for GG vs. AA+AG (OR=1.28, 95% CI=1.14-1.43) and G vs. A (OR=1.07, 95% CI=1.03-1.10). Further subgroup analysis based on ethnicity showed similar results in Asians and Caucasians. In the subgroup analysis of source of control, a significant association between the G allele and glioma susceptibility were found in population-based group and hospital-based group. CONCLUSIONS: The meta-analysis suggested that regulator of telomere elongation helicase 1 rs6010620 polymorphism was a risk factor for glioma. And this study also suggested that rs6010620 GG genotype and G allele may be indicators for the risk of glioma.
BACKGROUND:Glioma is the most devastating type of malignant brain tumors in adults. Genetic factors play important roles in the pathogenesis of glioma. In recent years, some studies found that there were significant association between regulator of telomere elongation helicase 1rs6010620 polymorphism and glioma susceptibility, however, the results were controversial. The aim of this study was to obtain a more exact estimation of the association between regulator of telomere elongation helicase 1rs6010620 polymorphism and glioma through a meta-analysis. METHODS: The meta-analysis included 19 published case-control studies involving 8541 cases and 14226 controls. The included papers were searched from PubMed and Embase database. Odds ratio (OR) with 95% confidence interval (95% CI) were used to evaluate the association of regulator of telomere elongation helicase 1rs6010620 polymorphism with glioma. RESULTS: A significant association between regulator of telomere elongation helicase 1rs6010620 polymorphism and glioma susceptibility was observed for GG vs. AA+AG (OR=1.28, 95% CI=1.14-1.43) and G vs. A (OR=1.07, 95% CI=1.03-1.10). Further subgroup analysis based on ethnicity showed similar results in Asians and Caucasians. In the subgroup analysis of source of control, a significant association between the G allele and glioma susceptibility were found in population-based group and hospital-based group. CONCLUSIONS: The meta-analysis suggested that regulator of telomere elongation helicase 1rs6010620 polymorphism was a risk factor for glioma. And this study also suggested that rs6010620 GG genotype and G allele may be indicators for the risk of glioma.
Entities:
Keywords:
Regulator of telomere elongation helicase 1; glioma; polymorphism; susceptibility
Authors: Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler Journal: Cancer Date: 2008-10-01 Impact factor: 6.860
Authors: Louise J Barber; Jillian L Youds; Jordan D Ward; Michael J McIlwraith; Nigel J O'Neil; Mark I R Petalcorin; Julie S Martin; Spencer J Collis; Sharon B Cantor; Melissa Auclair; Heidi Tissenbaum; Stephen C West; Ann M Rose; Simon J Boulton Journal: Cell Date: 2008-10-17 Impact factor: 41.582
Authors: Kyle M Walsh; Terri Rice; Paul A Decker; Matthew L Kosel; Thomas Kollmeyer; Helen M Hansen; Shichun Zheng; Lucie S McCoy; Paige M Bracci; Erik Anderson; George Hsuang; Joe L Wiemels; Alexander R Pico; Ivan Smirnov; Annette M Molinaro; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Daniel H Lachance; Hugues Sicotte; Jeanette E Eckel-Passow; John K Wiencke; Robert B Jenkins; Margaret R Wrensch Journal: Neuro Oncol Date: 2013-06-03 Impact factor: 12.300